Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration - PubMed (original) (raw)
. 2009 Sep;116(9):1169-78.
doi: 10.1007/s00702-009-0271-4. Epub 2009 Aug 1.
Corinna Hendrich, Anne-Dorte Sperfeld, Sarah Jesse, Stefan Lehnert, Alice Pabst, Christine A F von Arnim, Felix M Mottaghy, Ingo Uttner, Hayrettin Tumani, Albert Ludolph, Markus Otto
Affiliations
- PMID: 19649690
- DOI: 10.1007/s00702-009-0271-4
Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration
Petra Steinacker et al. J Neural Transm (Vienna). 2009 Sep.
Abstract
Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative disorders with heterogeneous clinical presentation but common neuropathological characteristics and pathophysiological substrates, which led to the view of ALS and FTLD representing two manifestations of a clinicopathological spectrum. For both diseases, changes in metabolism of beta-amyloid precursor protein (APP) are reported. In a pilot study, we analyzed cerebrospinal fluid from patients of the ALS-FTLD spectrum for APP processing products. ALS patients show elevated absolute levels of soluble APP and a shift towards the nonamyloidogenic APP processing pathway in contrast to patients with FTLD or ALS + FTLD. Changes in Abeta pattern could be described, allowing separation of patients with pure FTLD from ALS + FTLD. Combination of sAPP and Abeta values improves group differentiation. These findings may provide information on pathophysiological processes in the ALS-FTLD disease spectrum and could have impact in neurochemical diagnosis. We propose to expand this study to larger patient groups comprising followed up cases with known neuropathology.
Similar articles
- Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study.
Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL. Verwey NA, et al. J Alzheimers Dis. 2019;71(1):15-20. doi: 10.3233/JAD-190344. J Alzheimers Dis. 2019. PMID: 31356209 - TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CA, Lehnert S, Pabst A, Uttner I, Tumani H, Lee VM, Trojanowski JQ, Kretzschmar HA, Ludolph A, Neumann M, Otto M. Steinacker P, et al. Arch Neurol. 2008 Nov;65(11):1481-7. doi: 10.1001/archneur.65.11.1481. Arch Neurol. 2008. PMID: 19001167 Free PMC article. - A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, Lee EB, Van Deerlin VM, Shaw LM, Trojanowski JQ, Grossman M. Lleó A, et al. JAMA Neurol. 2018 Jun 1;75(6):738-745. doi: 10.1001/jamaneurol.2018.0118. JAMA Neurol. 2018. PMID: 29554190 Free PMC article. - Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
Neumann M. Neumann M. Rev Neurol (Paris). 2013 Oct;169(10):793-8. doi: 10.1016/j.neurol.2013.07.019. Epub 2013 Sep 5. Rev Neurol (Paris). 2013. PMID: 24011641 Review. - Neurodegeneration of brain networks in the amyotrophic lateral sclerosis-frontotemporal lobar degeneration (ALS-FTLD) continuum: evidence from MRI and MEG studies.
Trojsi F, Sorrentino P, Sorrentino G, Tedeschi G. Trojsi F, et al. CNS Spectr. 2018 Dec;23(6):378-387. doi: 10.1017/S109285291700075X. Epub 2017 Oct 27. CNS Spectr. 2018. PMID: 29076800 Review.
Cited by
- Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis.
Maranzano A, Verde F, Dubini A, Torre S, Colombo E, Doretti A, Gentile F, Manini A, Milone I, Brusati A, Peverelli S, Santangelo S, Spinelli EG, Torresani E, Gentilini D, Messina S, Morelli C, Poletti B, Agosta F, Ratti A, Filippi M, Silani V, Ticozzi N. Maranzano A, et al. Eur J Neurol. 2024 Sep;31(9):e16374. doi: 10.1111/ene.16374. Epub 2024 Jun 10. Eur J Neurol. 2024. PMID: 38853763 Free PMC article. - Sex-dependent effects of amyloid precursor-like protein 2 in the SOD1-G37R transgenic mouse model of MND.
Truong PH, Crouch PJ, Hilton JBW, McLean CA, Cappai R, Ciccotosto GD. Truong PH, et al. Cell Mol Life Sci. 2021 Oct;78(19-20):6605-6630. doi: 10.1007/s00018-021-03924-5. Epub 2021 Sep 2. Cell Mol Life Sci. 2021. PMID: 34476545 Free PMC article. - Prognostic Role of CSF β-amyloid 1-42/1-40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis.
Colletti T, Agnello L, Spataro R, Guccione L, Notaro A, Lo Sasso B, Blandino V, Graziano F, Gambino CM, Giglio RV, Bivona G, La Bella V, Ciaccio M, Piccoli T. Colletti T, et al. Brain Sci. 2021 Feb 27;11(3):302. doi: 10.3390/brainsci11030302. Brain Sci. 2021. PMID: 33673569 Free PMC article. - Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis.
Lanznaster D, Hergesheimer RC, Bakkouche SE, Beltran S, Vourc'h P, Andres CR, Dufour-Rainfray D, Corcia P, Blasco H. Lanznaster D, et al. Int J Mol Sci. 2020 Apr 21;21(8):2911. doi: 10.3390/ijms21082911. Int J Mol Sci. 2020. PMID: 32326346 Free PMC article. - CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.
Tang W, Wang Y, Cheng J, Yao J, Yao YY, Zhou Q, Guan SH. Tang W, et al. Neuromolecular Med. 2020 Mar;22(1):45-55. doi: 10.1007/s12017-019-08561-7. Epub 2019 Aug 14. Neuromolecular Med. 2020. PMID: 31414383
References
- Acta Neuropathol. 1999 May;97(5):463-8 - PubMed
- Neurobiol Dis. 2005 Jun-Jul;19(1-2):340-7 - PubMed
- Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11 - PubMed
- Neurosci Lett. 2001 May 25;304(3):161-4 - PubMed
- J Neural Transm (Vienna). 2007;114(5):621-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous